3.77
-0.31 (-7.60%)
| Previous Close | 4.08 |
| Open | 3.97 |
| Volume | 1,362,180 |
| Avg. Volume (3M) | 1,707,962 |
| Market Cap | 269,237,184 |
| Price / Sales | 1.94 |
| Price / Book | 10.88 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -58.36% |
| Operating Margin (TTM) | -48.33% |
| Diluted EPS (TTM) | -1.38 |
| Quarterly Revenue Growth (YOY) | 10.70% |
| Total Debt/Equity (MRQ) | 259.84% |
| Current Ratio (MRQ) | 1.86 |
| Operating Cash Flow (TTM) | -31.00 M |
| Levered Free Cash Flow (TTM) | -17.61 M |
| Return on Assets (TTM) | -16.54% |
| Return on Equity (TTM) | -132.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Neuronetics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 8.89% |
| % Held by Institutions | 49.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Accurate Wealth Management, Llc | 31 Dec 2024 | 78,927 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (Canaccord Genuity, 112.20%) | Buy |
| Median | 7.50 (98.94%) | |
| Low | 7.00 (Citizens Capital Markets, 85.68%) | Buy |
| Average | 7.50 (98.94%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 05 Mar 2025 | 8.00 (112.20%) | Buy | 5.42 |
| Citizens Capital Markets | 05 Mar 2025 | 7.00 (85.68%) | Buy | 5.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 May 2025 | Announcement | Neuronetics Reports First Quarter 2025 Financial and Operating Results |
| 05 May 2025 | Announcement | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 22 Apr 2025 | Announcement | Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call |
| 31 Mar 2025 | Announcement | Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression |
| 27 Mar 2025 | Announcement | Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results |
| 04 Mar 2025 | Announcement | Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results |
| 03 Mar 2025 | Announcement | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 21 Feb 2025 | Announcement | Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |